CA2285948A1 - Methodes et composition de modulation de l'amyloidose - Google Patents

Methodes et composition de modulation de l'amyloidose Download PDF

Info

Publication number
CA2285948A1
CA2285948A1 CA002285948A CA2285948A CA2285948A1 CA 2285948 A1 CA2285948 A1 CA 2285948A1 CA 002285948 A CA002285948 A CA 002285948A CA 2285948 A CA2285948 A CA 2285948A CA 2285948 A1 CA2285948 A1 CA 2285948A1
Authority
CA
Canada
Prior art keywords
blocker
abc
abc transporter
amyloid
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002285948A
Other languages
English (en)
Inventor
Fred Chiu-Lai Lam
Peter B. Reiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2285948A1 publication Critical patent/CA2285948A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes permettant de moduler le dépôt amyloïde chez un sujet. On administre au sujet une dose efficace d'au moins un inhibiteur de transporteur de cassette de liaison d'ATP (ABC), de manière à moduler le dépôt amyloïde. Ces méthodes consistent également à administrer au sujet une dose efficace d'au moins un inhibiteur de transporteur d'ABC ou d'un de ses sels pharmaceutiquement acceptables, de manière à traiter un état pathologique associé à l'amyloïdose. L'invention concerne aussi des compositions pharmaceutiques conditionnées permettant de traiter l'amyloïdose. Le conditionnement comprend un contenant destiné à renfermer une dose efficace d'une composition pharmaceutique ainsi que les instructions d'utilisation de ladite composition pour le traitement de l'amyloïdose. La composition pharmaceutique renferme au moins un inhibiteur d'ABC pour moduler le dépôt amyloïde chez un sujet. L'invention a en outre pour objet des procédés d'identification d'agents modulant le dépôt amyloïde chez un sujet. On administre à un organisme une dose efficace d'au moins un inhibiteur de transporteur d'ABC de manière à moduler le dépôt amyloïde.
CA002285948A 1997-04-28 1998-04-28 Methodes et composition de modulation de l'amyloidose Abandoned CA2285948A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84761697A 1997-04-28 1997-04-28
US08/847,616 1997-04-28
PCT/US1998/008463 WO1998048784A2 (fr) 1997-04-28 1998-04-28 Methodes et composition de modulation de l'amyloidose

Publications (1)

Publication Number Publication Date
CA2285948A1 true CA2285948A1 (fr) 1998-11-05

Family

ID=25301065

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002285948A Abandoned CA2285948A1 (fr) 1997-04-28 1998-04-28 Methodes et composition de modulation de l'amyloidose

Country Status (6)

Country Link
EP (1) EP0979086A2 (fr)
JP (1) JP2002504895A (fr)
AU (1) AU7260398A (fr)
CA (1) CA2285948A1 (fr)
IL (1) IL132169A0 (fr)
WO (1) WO1998048784A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042406A1 (fr) * 2004-10-20 2006-04-27 The Hospital For Sick Children Methode de modification de l'activite de $g(g)-secretase par inhibition de fkbp13

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
JP4503180B2 (ja) * 1998-08-14 2010-07-14 ジーピーアイ ニル ホールディングス インコーポレイテッド 視覚および記憶障害のための組成物および使用法
JP2000072749A (ja) * 1998-08-24 2000-03-07 Mitsui Chemicals Inc キノリン誘導体を用いるアポトーシス誘導剤
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
CA2346689A1 (fr) 1998-10-08 2000-04-20 Gregor James Macdonald Derives de tetrahydrobenzozepine utiles comme modulateurs des recepteurs de la la dopamine d3
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
WO2000055318A2 (fr) 1999-03-15 2000-09-21 University Of British Columbia Methodes et reactifs permettant de moduler les taux de cholesterol
EP1210422A2 (fr) * 1999-08-20 2002-06-05 Active Pass Pharmaceuticals, Inc. Nouveau transporteur abc2 et son utilisation
AR027878A1 (es) * 1999-11-05 2003-04-16 Wyeth Corp Metodos para identificar y utilizar compuestos inhibidores de amiloides
WO2001078709A2 (fr) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Traitement des maladies neurodegeneratives
US20020169137A1 (en) * 2001-02-09 2002-11-14 Active Pass Pharmaceuticals, Inc. Regulation of amyloid precursor protein expression by modification of ABC transporter expression or activity
AU2002304931A1 (en) * 2001-06-08 2002-12-23 University Of British Columbia Methods for treating disorders of the nervous and reproductive systems
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
WO2005105063A1 (fr) * 2004-05-03 2005-11-10 Universita' Degli Studi Di Firenze Compositions pharmaceutiques contenant des s.e.r.m. et utilisees dans le traitement de la maladie d'alzheimer
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
WO2011017319A1 (fr) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Méthodes de traitement de troubles associés à la polymérisation d'une protéine
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
WO2011056222A1 (fr) * 2009-11-05 2011-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Procédés de traitement de troubles associés à une agrégation protéique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
GB9205670D0 (en) * 1992-03-16 1992-04-29 Indena Spa New derivatives of physostigmine,their use and pharmaceutical formulations containing them
US5466696A (en) * 1992-09-10 1995-11-14 Warner Lambert Company Tacrine and cytochrome P450 oxidase inhibitors and methods of use
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5753640A (en) * 1995-06-07 1998-05-19 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5635496A (en) * 1993-03-09 1997-06-03 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
WO1996004915A1 (fr) * 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042406A1 (fr) * 2004-10-20 2006-04-27 The Hospital For Sick Children Methode de modification de l'activite de $g(g)-secretase par inhibition de fkbp13

Also Published As

Publication number Publication date
JP2002504895A (ja) 2002-02-12
WO1998048784A2 (fr) 1998-11-05
AU7260398A (en) 1998-11-24
WO1998048784A3 (fr) 1999-08-12
EP0979086A2 (fr) 2000-02-16
IL132169A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
US6660725B1 (en) Method and composition for modulating amyloidosis
EP0979086A2 (fr) Methodes et composition de modulation de l'amyloidose
US6221667B1 (en) Method and composition for modulating amyloidosis
US20020173511A1 (en) Serotonergic compositions and methods for treatment of mild cognitive impairment
MX2011005095A (es) Tratamiento de proteinopatias usando un inhibidor de farnesil transferasa.
KR100713573B1 (ko) Ｃｇｒｐ 길항제 및 ｃｇｒｐ 방출 억제제를 함유하는 폐경기 안면홍조 치료용 약제학적 조성물
JP6267160B2 (ja) アルツハイマー病等を含む神経疾患の１，２５ｄ３−ｍａｒｒｓが関与する治療薬及び治療法
US20080027052A1 (en) Methods for treating cystic kidney disease
CN105473591A (zh) 作为神经保护剂的EphA4抑制剂
US7101879B2 (en) Treatments for neurotoxicity in Alzheimer's Disease
US7067550B2 (en) Treatments for neurotoxicity in Alzheimer's Disease
US10881642B2 (en) Autophagy enhancer and use thereof
DE69933885T2 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
US20190262323A1 (en) Compositions and methods for treating neurodegenerative disorders
CA2568213C (fr) Composition et procede de traitement de tauopathies
EP4534545A1 (fr) Nouveau peptide et son utilisation
US20150080294A1 (en) Methods for promoting lipolysis and oxidation in liver and adipose tissue using catestatin
EP4534546A1 (fr) Nouveau peptide et son utilisation
WO2018012769A1 (fr) Matériau améliorant l'autophagie et utilisation associée
EA048938B1 (ru) Комбинация антагониста cxcr7 с модулятором рецептора s1p1

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued